Variant · Snv
FGFR3 P449S
CI-VAR-00003348Explore in graph →NP_001156685.1:p.Pro451SerNM_001163213.1:c.1351C>TClinVar 134409 CIViC 4558
Curated evidence
Evidence by cancer (1 items)
Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.
- Source
- CIViC — Clinical Interpretation of Variants in Cancer
- Dataset
- CIViC evidence items
- Version
- civic-2026-09-08
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- expert curation
- License
- CC0 1.0
- PMID
- 40526877
- Run
- ING-CIVIC-20260908-000001
| Molecular profile | Therapy | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| Malignant Neoplasm1 | ||||||||
| FGFR3 P449S | (oncogenic) | Oncogenic | D | Does Not Support Oncogenicity | 3 | submitted | EID13089High-throughput screening. Used Ba/F4 cells - murine pro-B cell line, which is dependent on IL-3 for survival. ED50WT/ED50 variant ratio to measure the relative sensitivity of Ba/F3 cells expressing F… (full text at CIViC) PMID 40526877 · Ziegler et al., 2025 · Open in CIViC | civic |
ClinVar
Clinical significance (0)
ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.
Data not yet available